Entity

Time filter

Source Type


Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Revue des Maladies Respiratoires Actualites | Year: 2015

The TNM classification has changed in 2009 on the basis of a new methodological approach. The various modifications of the system and the associated works are reviewed. The potential improvements in prognostic and operational terms are discussed. © 2015 Elsevier Ltd. Source


Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Revue des Maladies Respiratoires Actualites | Year: 2014

Over 85 % of patients with non small cell lung carcinoma (NSCLC) have no EGFR activating mutation, their management in first line treatment is the daily life of doctors who have interest in lung cancer. Chemotherapy proved to be useful compared to supportive care from many years. The standard chemotherapy regimen should be a platinumbased combination, first with cisplatin if the patient's condition and comorbidities allow it. Combination therapy rather than monotherapy is beneficial, including elderly patients or those with a performance status 2. If cisplatin can't be used, a combination therapy with or without carboplatin can be chosen. The choice of the second agent. in combination with cisplatin should be guided by the potential side effects and the histology, strategies based on the presence of an overactivation of some proteins (for example ERCC1) have not yet proven their effectiveness. Except adding bevacizumab to combination therapy, there is no place for targeted therapies in first-line treatment of NSCLC. © 2014 Elsevier Masson SAS. Source


Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Meert A.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
European Respiratory Review | Year: 2014

The objective of this review is to report the Clinical Year in Review proceedings in the field of thoracic oncology that were presented at the 2013 European Respiratory Society Annual Congress in Barcelona, Spain. Various topics were reviewed, including: epidemiology, screening, histology, and treatment of nonsmall cell lung cancer and small cell lung cancer. © ERS 2014. Source


Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Meert A.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
European Respiratory Review | Year: 2015

Herein, we have reviewed and analysed recent literature, published in 2013 and early 2014, in the context of pre-existing data. Considered target therapies were tyrosine kinase inhibitors of active epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib and afatinib), anaplastic lymphoma kinase rearrangements (e.g. crizotinib) or angiogenesis (drugs under development), or monoclonal antibodies against vascular endothelial growth factor (e.g. bevacizumab) or epidermal growth factor receptors (e.g. cetuximab). The therapeutic project has to consider tyrosine kinase inhibitors in the case of nonsmall cell lung cancer with active epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangement. However, these drugs should not be used in the absence of the targeted genetic abnormalities. ©ERS 2015. Source


Morelle I.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Berghmans T.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Cstoth I.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Sculier J.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb | Meert A.-P.,Center Des Tumeurs Of Luniversite Libre Of Bruxelles Ulb
Revue des Maladies Respiratoires | Year: 2014

In Belgium in 2008, the body responsible for compensating and indemnifyingvictims of occupational diseases recognized 62 cases of lung cancer, although 702 cases wereexpected. There is an 'underreporting' of occupational lung cancer. This study aimed to assessthe number of cases of occupational lung cancer in a Belgian hospital specialized in oncology.Patient and method. - From September 1st, 2009 to January 31st, 2011, each new patientwith lung cancer has been directed to a consultation identifying occupational exposure to lungcarcinogens.Results. - Among 81 occupational histories, 28 patients (35%) were found to have been defini-tely or probably exposed to one or more lung carcinogens (known or suspected). These patientswere all male, mostly blue collar workers. Thirteen compensation claims for occupationaldisease have been introduced: nine recognized, one rejected and three pending.Conclusion. - This study demonstrates the importance of a physician trained in occupationaldiseases within a thoracic oncology unit in reducing the 'underreporting' of occupational lungcancer and thus providing the victims with the compensation to which they are legitimatelydue.© 2013 SPLF. Published by Elsevier Masson SAS. All rights reserved. Source

Discover hidden collaborations